Lv5
1160 积分 2021-11-08 加入
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
21天前
已完结
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
24天前
已完结
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study
26天前
已完结
How I treat HLH-like toxicities after immune effector cell therapy
29天前
已完结
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
1个月前
已完结
Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study
2个月前
已完结
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
2个月前
已完结
Peripheral T-Cell Lymphoma: Moving Toward Targeted Therapies
2个月前
已完结
De-escalation trials in multiple myeloma: past, present and future
3个月前
已完结
Up-Front Treatment of Elderly (Age ≥75 Years) and Frail Patients With Multiple Myeloma
3个月前
已关闭
皖公网安备34019202002308
